Enhancing R&D Decision Making: Lessons from Eli Lilly’s Probability Assessment Framework
Date: February 25
Time: 6:00 PM ET
Place: Online
Event Description:
Join the SDP Boston Chapter for an engaging online discussion featuring Charles Persinger and Jay Andersen, who will share key insights from their extensive work in decision sciences and portfolio management at Eli Lilly. Discover how quantitative probability assessments have shaped 26 years of portfolio decisions, improving technical feasibility evaluations and investment strategies in pharmaceutical R&D.
Read more about this topic on LinkedIn: Probability Assessments at Eli Lilly
This session will explore:
- Structured decision processes for R&D portfolio management
- Mitigating biases in probability assessment
- Performance calibration for informed investment decisions
Don’t miss this opportunity to gain practical takeaways for professionals in drug development, strategy, and risk management!
Speakers:
Charles Persinger
Associate Vice President, R&D Strategy, Eli Lilly
Charles leads Lilly’s Decision Sciences group and has over 20 years of experience enabling decision quality in drug development. Under his leadership, Lilly earned the Raiffa-Howard Award for Organizational Decision Quality in 2016.
Jay Andersen
Fellow & Two-Time Board Member, Society of Decision Professionals
Jay holds a PhD in statistics and retired as Senior Research Fellow from Eli Lilly after a 28-year career. He now leads Oaken Table Consulting, specializing in decision consulting for portfolio management and probability assessment processes.